TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05639049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enova GF3
Description: Enova GF3, monofocal IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis 1-piece ZCB00
Description: Tecnis 1-piece ZCB00, monofocal IOL
Study: NCT06312839

Intervention type: OTHER
Intervention: Collecting data from the medical record
Description: Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay

Intervention type: OTHER
Intervention: Collecting data from the medical record
Description: Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay
Study: NCT05520905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TelePrEP
Description: HIV pre-exposure prophylaxis delivered via telemedicine.
Study: NCT04880759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bike desks in the classroom
Description: Children will use bike desks for 13 weeks during school time
Study: NCT05222230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP3 Mask
Description: Participans will wear FFP3 respirators during the study.
Study: NCT05715606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
Study: NCT05409599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises
Study: NCT04972006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote, intensive intervention for injection phobia
Description: The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote, intensive intervention for injection phobia
Description: The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote, intensive intervention for injection phobia
Description: The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
Study: NCT05323500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Senobi breathing exercises
Description: The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
Study: NCT05449327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
Study: NCT05861440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: adjunct steroid per study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard anti-tuberculosis agents
Description: standard anti-tuberculosis agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard anti-tuberculosis agents
Description: standard anti-tuberculosis agents
Study: NCT05742373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training in the fasted state
Description: Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training in the fed state
Description: Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
Study: NCT05287867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)
Description: Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything.
Study: NCT06578819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: doll therapy
Description: Doll therapy will be applied to the experimental group 4 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: doll therapy
Description: Doll therapy will be applied to the experimental group 4 days a week.
Study: NCT06577961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
Study: NCT06578052

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan liposome Capecitabine
Description: Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs.
Study: NCT05220982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Training Therapy
Description: Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Global Voice Prevention and Therapy Model
Description: Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Conversation Training Therapy
Description: Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Global Voice Prevention and Therapy Model
Description: Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
Study: NCT05835440

Intervention type: OTHER
Intervention: no intervention
Description: interviews

Intervention type: OTHER
Intervention: no intervention
Description: interviews
Study: NCT05971784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The group that will receive an exercise program consisting of balance and walking activities
Study: NCT05508074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 50mg/day
Description: Tested product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 100mg/day
Description: Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 100mg/day
Description: Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
Study: NCT05134259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
Study: NCT04522011

Intervention type: OTHER
Intervention: intraoperative or postoperative hyperthermic intraperitoneal chemotherapy
Description: Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour

Intervention type: OTHER
Intervention: intraoperative or postoperative hyperthermic intraperitoneal chemotherapy
Description: Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
Study: NCT05202613

Intervention type: DRUG
Intervention: Doravirine
Description: Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
Study: NCT05792865

Intervention type: DRUG
Intervention: paxlovid
Description: Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.

Intervention type: DRUG
Intervention: No paxlovid
Description: Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.

Intervention type: DRUG
Intervention: Paxlovid
Description: Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.
Study: NCT05659706

Intervention type: OTHER
Intervention: cognitive evaluations and non cognitive evaluations
Description: Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)

Intervention type: OTHER
Intervention: cognitive evaluations and non cognitive evaluations
Description: Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
Study: NCT05028751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally via tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally via tablets
Study: NCT05396443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Girls for Wellness Telehealth
Description: Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
Study: NCT06573684

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: All of groups will have assessment of electromyography result
Study: NCT05241197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Load Training
Description: All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
Study: NCT06573684

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: All of groups will have assessment of electromyography result

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: All of groups will have assessment of electromyography result
Study: NCT06394531

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jaboticaba Peel Extract
Description: Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
Study: NCT05358561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed and Chia
Description: Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed and Chia
Description: Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed and Chia
Description: Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed and Chia
Description: Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
Study: NCT05082090

Intervention type: PROCEDURE
Intervention: Spinal Surgery
Description: Implanted with Orthofix Spinal products
Study: NCT04669704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Tablet application
Description: A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Conventional treatment
Description: In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
Study: NCT05841966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoral Ultrasound
Description: The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
Study: NCT05831995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-168
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-168
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
Study: NCT05207059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELMS Lifestyle Intervention
Description: The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
Study: NCT05831995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-168
Description: Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
Study: NCT06460961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6837
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6837
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study: NCT04853238

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study. No study treatment was administered in this study.

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study. No study treatment was administered in this study.

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study. No study treatment was administered in this study.
Study: NCT05758779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visualization of coronary Imaging and oral description
Description: The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
Study: NCT06442371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity interval training + Quranic Listening
Description: In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation